FAM
RPRX icon

Formidable Asset Management’s Royalty Pharma RPRX Stock Holding History

Formidable Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.59M Sell
32,010
-11,959
-27% -$622K 0.25% 81
2026
Q1 		$1.87M Sell
43,969
-11,768
-21% -$515K 0.29% 68
2025
Q4 		$2.07M Buy
55,737
+19,540
+54% +$745K 0.3% 61
2025
Q3 		$1.29M Buy
36,197
+772
+2% +$27.9K 0.2% 92
2025
Q2 		$1.23M Sell
35,425
-1,450
-4% -$48K 0.21% 92
2025
Q1 		$1.15M Sell
36,875
-36
-0.1% -$1.14K 0.19% 99
2024
Q4 		$942K Buy
36,911
+4,226
+13% +$112K 0.15% 126
2024
Q3 		$925K Sell
32,685
-898
-3% -$24.9K 0.15% 134
2024
Q2 		$886K Sell
33,583
-3,844
-10% -$107K 0.14% 137
2024
Q1 		$1.14M Sell
37,427
-3,183
-8% -$93.8K 0.19% 112
2023
Q4 		$1.14M Sell
40,610
-936
-2% -$25.7K 0.24% 80
2023
Q3 		$1.12M Buy
41,546
+5,022
+14% +$149K 0.25% 79
2023
Q2 		$1.12M Buy
36,524
+3,666
+11% +$124K 0.25% 76
2023
Q1 		$1.18M Buy
32,858
+8,137
+33% +$302K 0.25% 76
2022
Q4 		$977K Buy
24,721
+3,431
+16% +$143K 0.22% 89
2022
Q3 		$856K Buy
21,290
+567
+3% +$24.2K 0.2% 96
2022
Q2 		$872K Buy
20,723
+2,131
+11% +$87.4K 0.2% 100
2022
Q1 		$724K Buy
18,592
+8,350
+82% +$328K 0.14% 132
2021
Q4 		$408K Sell
10,242
-7,238
-41% -$281K 0.08% 211
2021
Q3 		$632K Buy
17,480
+920
+6% +$35.8K 0.12% 167
2021
Q2 		$660K Buy
+16,560
New +$704K 0.14% 152

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Formidable Asset Management's RPRX Position: Q2 2026 in Review

Formidable Asset Management reduced its Royalty Pharma (RPRX) stake by 27% in Q2 2026, selling an estimated $622K and leaving 32,010 shares worth $1.59M. The position accounts for 0.25% of the portfolio, ranked #81.

Formidable Asset Management first reported a position in RPRX in Q2 2021 and has held it in 21 quarters since. The position peaked at $2.07M in Q4 2025. 644 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Formidable Asset Management held 32,010 shares of Royalty Pharma worth $1.59M as of Q2 2026.
  • Formidable Asset Management sold 11,959 Royalty Pharma shares in Q2 2026, an estimated $622K.
  • Royalty Pharma made up 0.25% of Formidable Asset Management's portfolio in Q2 2026, its #81 holding.
  • Formidable Asset Management first reported a position in Royalty Pharma in Q2 2021 and has held it in 21 quarters since.
  • Formidable Asset Management's Royalty Pharma position peaked at $2.07M in Q4 2025.
  • 644 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Formidable Asset Management's 13F filing for Q2 2026, filed 17 Jul 2026.